754 Phase 1 trial of LYL797, a ROR1-targeted CAR T-cell therapy enhanced with genetic and epigenetic reprogramming, in advanced triple-negative breast cancer (TNBC) and non-small cell lung cancer (NSCLC)

• Haven Garber,
• Saranya Chumsri,
• Yazan Migdady,
• Chul Kim,
• Erika Hamilton,
• Jennifer Specht,
• Babar Bashir,
• Hirva Mamdani,
• Heidi Gillenwater,
• Yeonhee Kim,
• David R Spigel,
• Usama Gergis,
• Hemant S Murthy,
• Lubna N Chaudhary,
• Sarah Fitzsimmons,
• Bishwa J Ganguly,
• Hajime Hiraragi,
• Helle Jensen,
• Mary C Lessig

Affiliations

Haven Garber

7The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Saranya Chumsri

3Mayo Clinic, Jacksonville, FL, USA

Yazan Migdady

Aff2 0000000419368956grid.168010.ePathology Department, Transfusion MedicineStanford School of Medicine, Stanford Hospital 300 Pasteur Drive, Rm H1402 94305-5626 Stanford CA USA

Chul Kim

2 Division of Hematology and Oncology, Georgetown Lombardi Comprehensive Cancer Center, Georgetown University, Washington, District of Columbia, USA

Erika Hamilton

7Sarah Cannon Research Institute, Nashville, TN, USA

Jennifer Specht

2Fred Hutchinson Cancer Research Center, Seattle, WA, USA

Babar Bashir

2Thomas Jefferson University, Philadelphia, PA, USA

Hirva Mamdani

1Barbara Ann Karmanos Cancer Institute, Wayne State University, Detroit, MI, USA

Heidi Gillenwater

Bristol Myers Squibb, Seattle, WA, USA

Yeonhee Kim

Bristol Myers Squibb, Seattle, WA, USA

David R Spigel

1Sarah Cannon Research Institute, Nashville, TN, USA

Usama Gergis

2Thomas Jefferson University, Philadelphia, PA, USA

Hemant S Murthy

3Mayo Clinic, Jacksonville, FL, USA

Lubna N Chaudhary

6Medical College of Wisconsin, Milwaukee, WI, USA

Sarah Fitzsimmons

10Lyell Immunopharma, Seattle, WA, USA

Bishwa J Ganguly

11Lyell Immunopharma, South San Francisco, CA, USA

Hajime Hiraragi

11Lyell Immunopharma, South San Francisco, CA, USA

Helle Jensen

10Lyell Immunopharma, Seattle, WA, USA

Mary C Lessig

10Lyell Immunopharma, Seattle, WA, USA